WHIM Syndrome 1 — Comprehensive Disease Characteristics Report

Disease: WHIM Syndrome 1 (Warts, Hypogammaglobulinemia, Infections, Myelokathexis) MONDO ID: MONDO:8000006 Category: Mendelian, autosomal dominant combined primary immunodeficiency Causal gene: CXCR4 (C-X-C chemokine receptor type 4)

Summary

WHIM Syndrome 1 is a rare, autosomal dominant combined primary immunodeficiency and chronic neutropenic disorder caused by heterozygous gain-of-function truncating mutations in the intracellular C-terminal tail of the chemokine receptor gene CXCR4 (most commonly p.R334X). The acronym encodes the four cardinal features — Warts, Hypogammaglobulinemia, Infections, and Myelokathexis. The unifying molecular lesion is loss of the receptor's C-terminal serine/threonine phosphorylation sites, which normally recruit GRK6 and β-arrestin to desensitize and internalize the receptor after ligand binding. Truncation uncouples CXCR4 from this "off switch," producing sustained, exaggerated signaling in response to its sole ligand CXCL12/SDF-1 (increased calcium flux, ERK phosphorylation, and chemotaxis). Because the CXCL12–CXCR4 axis is the master retention signal for mature leukocytes in the bone marrow, hyperactive CXCR4 traps mature neutrophils (and other leukocytes) in the marrow — the hallmark myelokathexis — yielding paradoxical peripheral neutropenia and panleukopenia despite a hypercellular marrow.

Clinically, patients present in early childhood with severe congenital neutropenia, recurrent bacterial infections (especially pneumonia), a disproportionate susceptibility to human papillomavirus (HPV)-driven warts and anogenital malignancy, and variable hypogammaglobulinemia with B- and T-lymphopenia. Long-term complications include bronchiectasis and HPV-related cancers. Diagnosis is frequently delayed by a decade or more because myelokathexis requires specialized bone-marrow evaluation and penetrance is incomplete.

The disease has become a landmark example of mechanism-to-medicine translation. Because pathology stems from CXCR4 hyperactivity, CXCR4 antagonism reverses the leukocyte sequestration: the oral small-molecule antagonist mavorixafor (Xolremdi) became the first FDA-approved targeted therapy for WHIM syndrome on 26 April 2024, following a positive phase 3 trial. Complementary curative strategies exploit the fact that lowering CXCR4 gives hematopoietic stem cells a competitive advantage: a patient was spontaneously cured by chromothripsis that deleted the disease allele, and CRISPR-based disease-allele inactivation offers a proof-of-concept genetic cure.

1. Disease Information

Overview. WHIM syndrome is a rare inherited immunodeficiency defined by the tetrad of Warts, Hypogammaglobulinemia, recurrent bacterial Infections, and Myelokathexis (retention/apoptosis of mature neutrophils in the bone marrow). It is classified as an autosomal dominant combined immunodeficiency (CID) with an early-onset hallmark of neutropenia (PMID: 41451822; PMID: 29066537).

Key identifiers. | Resource | Identifier | |----------|-----------| | MONDO | MONDO:8000006 | | OMIM | #193670 (WHIM syndrome 1, WHIMS1) | | Gene | CXCR4, OMIM *162643; HGNC:2561 | | Orphanet | ORPHA:51636 | | MeSH | WHIM syndrome / Warts, hypogammaglobulinemia, infections, and myelokathexis syndrome | | ICD-10 | D84.8 (other specified immunodeficiencies) / D70 (neutropenia) |

Synonyms / alternative names. Warts–hypogammaglobulinemia–infections–myelokathexis syndrome; WHIMS; WHIMS1; historical "myelokathexis" descriptions (now attributed to CXCR4). "WHIM Syndrome 1" specifically denotes the CXCR4-associated form (the canonical and by far most common genotype).

Information source. The knowledge base entry is derived from aggregated disease-level resources — international patient cohorts, case series, mechanistic in vitro and mouse studies, and clinical trials — rather than from a single individual EHR.

2. Etiology

Primary causal factor — genetic. WHIM Syndrome 1 is caused by heterozygous, autosomal dominant, gain-of-function truncating mutations in the CXCR4 gene, which encodes a seven-transmembrane G-protein-coupled chemokine receptor. Mutations truncate the intracellular C-terminal tail, removing the serine/threonine residues required for receptor desensitization (PMID: 31313072; PMID: 36883568; PMID: 12692554).

"WHIM syndrome is usually caused by autosomal dominant mutations in the G protein-coupled chemokine receptor CXCR4 that impair desensitization, resulting in enhanced and prolonged G protein- and β-arrestin-dependent responses" (PMID: 31313072).

Genetic risk factors. The disease-causing variants are the risk factors — there are no separate susceptibility loci. The single largest genetic risk factor is inheriting one WHIM CXCR4 allele; p.R334X (c.1000C>T) is the most frequent variant. Additional described variants include p.Ser338X, p.Gly336X, p.Leu317fsX3, and an N-terminal p.D84H variant that expands the spectrum beyond the canonical C-terminal hotspot (PMID: 36883568; PMID: 41451822). Notably, some patients with full clinical WHIM carry a wild-type CXCR4 gene yet share the same CXCR4 signaling dysfunction, implying rare non-CXCR4 or upstream/downstream causes (genetic heterogeneity) (PMID: 21178277).

Environmental risk factors. No environmental exposure causes WHIM. However, HPV exposure is the necessary environmental trigger for the wart/malignancy phenotype: the immune defect renders patients unable to control HPV once acquired. Bacterial pathogens drive the infection phenotype but are opportunistic consequences of neutropenia, not causes of the disease.

Protective factors. The most striking protective factor is genetic: CXCR4 haploinsufficiency (loss of one functional copy) confers a hematopoietic stem-cell engraftment advantage and can reverse disease. A WHIM patient was cured when a chromothriptic event deleted the disease allele (PMID: 25662009). No dietary or lifestyle protective factors are established.

Gene–environment interaction. The genetic lesion (CXCR4 gain-of-function → immune-cell dysfunction) interacts with environmental HPV exposure to produce warts and cancer; mouse studies show WHIM animals are markedly more susceptible to papillomavirus-induced disease specifically because of immune-cell dysfunction, and bone-marrow transplant from wild-type donors normalizes susceptibility (PMID: 39226327).

3. Phenotypes

WHIM is a multisystem immunodeficiency. Frequencies below derive chiefly from an international cohort of 18 patients and a review of 105 published cases (PMID: 30716504).

Age of onset. Clinical features typically manifest at 2.2 ± 2.6 years, but diagnosis is delayed to a mean of 12.5 ± 10.4 years (PMID: 30716504).

Severity/progression. Neutropenia and myelokathexis are stable and lifelong; infections are episodic; bronchiectasis and HPV malignancy are progressive complications. Lymphopenia is selective — CD8⁺ T-cell lymphopenia is more severe than CD4⁺, due to sequestration in the thymus and bone marrow (PMID: 37133343).

"Pneumonia recurrence was observed in 61% of patients and was complicated with bronchiectasis in 27%. Skin warts were observed in 61% of patients at a mean age of 11 years, whereas human papilloma virus (HPV)-related malignancies manifested in 16% of patients." (PMID: 30716504)

Quality of life impact. Recurrent infections, chronic wart burden (disfiguring, refractory), IVIG dependence, and progressive lung disease substantially impair daily functioning; formal EQ-5D/SF-36 datasets specific to WHIM are not available. Despite severe neutropenia, the overall clinical course is frequently milder and more manageable than the laboratory picture suggests (PMID: 36793393).

4. Genetic / Molecular Information

Causal gene. CXCR4 (chromosome 2q22.1; historically mapped by linkage to 2q21). HGNC:2561; OMIM *162643. Encodes a 352-residue GPCR whose sole ligand is CXCL12 (SDF-1).

Gene discovery. Hernandez et al. (2003) localized WHIM to chromosome 2q21 and identified truncating mutations in the cytoplasmic tail domain of CXCR4 — the first example of a chemokine receptor causing a human Mendelian disease (PMID: 12692554).

"the identification of truncating mutations in the cytoplasmic tail domain of the gene encoding chemokine receptor 4 (CXCR4)" (PMID: 12692554)

"Lymphoblastoid cell lines carrying a 19-residue truncation mutation show significantly greater calcium flux relative to control cell lines in response to the CXCR4 ligand, SDF-1, consistent with dysregulated signaling by the mutant receptor" (PMID: 12692554)

Pathogenic variants. | Variant | cDNA | Type | Consequence | Notes | |---------|------|------|-------------|-------| | p.R334X | c.1000C>T | Nonsense/truncating | Removes ~19 C-terminal residues | Most common WHIM allele | | p.S338X | — | Nonsense/truncating | C-terminal truncation | Recurrent | | p.G336X | — | Nonsense/truncating | C-terminal truncation | Recurrent | | p.Leu317fsX3 | — | Frameshift | Truncation with altered signaling profile | Reduced G-protein signaling despite impaired internalization (PMID: 36883568) | | p.D84H | — | Missense (N-terminal) | Non-canonical activation | Expands genetic spectrum (PMID: 41451822) |

• Classification (ACMG/AMP): Pathogenic (recurrent truncating variants with established functional gain-of-function mechanism).
• Variant type: Predominantly nonsense/frameshift truncations of the C-terminal tail; rarely missense.
• Allele frequency: Absent/ultra-rare in gnomAD (consistent with a severe dominant disease).
• Origin: Germline, inherited autosomal dominant (or de novo). Not somatic in origin (except the acquired somatic chromothriptic reversion event that cured one patient).
• Functional consequence: Gain of function — enhanced and prolonged signaling due to impaired desensitization; not a simple loss of function.

"All mutations reported in WHIM patients lead to the truncations in the C-terminal domain of CXCR4, R334X being the most frequent. This defect prevents receptor internalization and enhances both calcium mobilization and ERK phosphorylation, resulting in increased chemotaxis in response to the unique ligand CXCL12." (PMID: 36883568)

Modifier genes. No formally validated modifier genes; the marked clinical variability (incomplete penetrance, variable expressivity, WHIM without hypogammaglobulinemia/warts) suggests genetic and stochastic modifiers exist but are not yet mapped.

Epigenetic information. No disease-specific DNA-methylation or histone-modification signature has been established for WHIM.

Chromosomal abnormalities. Not a cause of WHIM. However, a spontaneous chromothripsis event — deleting the CXCR4^R334X allele plus 163 neighboring genes from one copy of chromosome 2 in a single HSC — produced a natural cure, an instructive example of a large-scale acquired somatic rearrangement reversing a dominant disease (PMID: 25662009).

"deletion of the disease allele, CXCR4(R334X), as well as 163 other genes from one copy of chromosome 2 occurred in a hematopoietic stem cell (HSC) that repopulated the myeloid but not the lymphoid lineage" (PMID: 25662009)

5. Environmental Information

• Environmental factors: No toxins, radiation, or occupational exposures cause WHIM.
• Lifestyle factors: None established as causal or protective.
• Infectious agents: Infections are consequences of the immunodeficiency, not causes. The most clinically important pathogen is human papillomavirus (HPV), to which patients are disproportionately susceptible, driving warts and anogenital/cervical/head-and-neck carcinomas (PMID: 30716504; PMID: 39226327). Recurrent encapsulated-bacterial infections (pneumonia, otitis, cellulitis, sepsis) result from neutropenia and hypogammaglobulinemia.

6. Mechanism / Pathophysiology

Ordered causal chain

1. A heterozygous truncating mutation in the CXCR4 C-terminal tail (e.g., p.R334X) removes the serine/threonine phosphorylation cluster required for receptor regulation. (demonstrated)
2. The truncated receptor fails to recruit GRK6 (while GRK3 binding is preserved) and shows delayed β-arrestin2 recruitment, which impairs receptor phosphorylation, internalization, and desensitization. (demonstrated, in vitro) (PMID: 19956569)
3. Impaired desensitization leads to sustained and exaggerated CXCR4 signaling in response to CXCL12 — increased calcium mobilization, prolonged ERK phosphorylation, and enhanced chemotaxis. (demonstrated) (PMID: 36883568; PMID: 12692554)
4. At the membrane, the mutant receptor fails to nanocluster after CXCL12 stimulation, producing inadequate β-arrestin1-dependent actin remodeling and defective chemotactic gradient sensing. (demonstrated, single-particle tracking) (PMID: 35588454)
5. Because CXCL12–CXCR4 is the master retention signal keeping leukocytes in the bone-marrow niche, hyperactive CXCR4 results in failure of mature neutrophils to egress → they accumulate and undergo apoptotic senescence in the marrow → myelokathexis. (demonstrated) (PMID: 29734477; PMID: 21890643)
6. Retention leads to peripheral neutropenia and panleukopenia (lymphocytes and monocytes are also sequestered; ALC > monocyte > neutrophil in responsiveness to CXCR4 blockade). (demonstrated pharmacologically) (PMID: 21890643)

Branch A — antibacterial defense: Neutropenia + hypogammaglobulinemia + impaired B-cell trafficking → recurrent bacterial infections → pneumonia → bronchiectasis.

Branch B — antiviral/antitumor defense: Selective CD8⁺ > CD4⁺ T lymphopenia via sequestration in thymus and bone marrow (PMID: 37133343) + reduced lymphocyte infiltration into infected tissue → failure to control HPV → refractory warts → HPV-driven malignancy (PMID: 39226327).

1. Overall, CXCR4 hyperactivation disrupts stromal niches critical for lymphocyte development and survival, producing the combined immunodeficiency phenotype. (inferred/demonstrated in models) (PMID: 41451822)

Supporting detail

• Molecular pathways. CXCL12→CXCR4→Gαi (inhibits adenylyl cyclase; PI3K/AKT; MAPK/ERK) and β-arrestin scaffolding. The regulatory lesion is at the GRK/β-arrestin desensitization module (Reactome: "Signaling by GPCR"; GPCR desensitization). Downstream ERK1/2 activation is prolonged.
• Cellular processes. Impaired cell migration/chemotaxis (GO:0006935), defective receptor internalization (GO:0031623 receptor internalization; GO:0002031 GPCR internalization), leukocyte retention, actin cytoskeleton remodeling (GO:0030036), neutrophil apoptosis/senescence.
• Protein dysfunction. Truncated GPCR with intact ligand binding and surface expression but defective regulatory phosphorylation → gain-of-function signaling. Surface expression and internalization of receptor were shown unaffected in some patients while chemotaxis was enhanced (PMID: 15026312).
• Immune system involvement. Combined immunodeficiency: neutropenia + B-lymphopenia (reduced memory B cells) + T-cell abnormalities (accumulation of effector memory T cells, restricted TCR repertoire, severe CD8 lymphopenia) + variable hypogammaglobulinemia (PMID: 15026312; PMID: 37133343).
• Tissue damage. Chronic pulmonary infection → airway destruction → bronchiectasis; HPV-driven epithelial dysplasia → carcinoma.
• Biochemical abnormality. GPCR desensitization defect (receptor regulation, not enzyme deficiency).

"while both kinases Grk3 and Grk6 bind to WT CXCR4 and are critical to its trafficking to the lysosomes, Grk6 fails to associate with the WHIM-mutant receptor whereas Grk3 associates normally" (PMID: 19956569)

"CXCR4R334X, a truncated mutant chemokine receptor linked to WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis), fails to nanocluster after CXCL12 stimulation" (PMID: 35588454)

GO term suggestions: GO:0006935 (chemotaxis), GO:0002031 (GPCR internalization), GO:0007204 (positive regulation of cytosolic calcium), GO:0070098 (chemokine-mediated signaling), GO:0002686 (negative regulation of leukocyte migration). CL term suggestions: CL:0000775 (neutrophil), CL:0000625 (CD8⁺ αβ T cell), CL:0000624 (CD4⁺ αβ T cell), CL:0000236 (B cell), CL:0000576 (monocyte), CL:0000037 (hematopoietic stem cell). CHEBI term suggestions: CHEBI:calcium(2+) ion (second messenger); mavorixafor and plerixafor as CXCR4-antagonist small molecules.

7. Anatomical Structures Affected

Organ level. - Primary: Bone marrow (UBERON:0002371) — site of myelokathexis; hematopoietic/immune system (UBERON:0002390 hematopoietic system; UBERON:0002405 immune system). - Secondary: Lung (UBERON:0002048) → recurrent pneumonia and bronchiectasis; skin (UBERON:0002097) and anogenital mucosa → HPV warts and dysplasia; thymus (UBERON:0002370) → T-cell sequestration; occasionally heart (UBERON:0000948) → congenital cardiac defects. - Body systems: Hematologic, immune, respiratory, integumentary; occasionally cardiovascular.

Tissue and cell level. Bone-marrow myeloid tissue (accumulated mature neutrophils with hypersegmented, apoptotic nuclei); respiratory epithelium (infection-related damage); squamous epithelium (HPV). Cell populations affected: neutrophils (CL:0000775), CD8⁺ and CD4⁺ T lymphocytes, B lymphocytes, monocytes, and hematopoietic stem/progenitor cells whose egress is impaired.

Subcellular level. Plasma-membrane GPCR signaling machinery (GO:0005886 plasma membrane); endocytic/lysosomal trafficking machinery is functionally engaged but the mutant receptor evades normal trafficking to lysosomes (GO:0005764 lysosome); β-arrestin/clathrin endocytic compartment (GO:0005905 clathrin-coated pit).

Localization / lateralization. Systemic and bilateral (marrow-wide, systemic leukopenia); warts and infections are distributed per exposure (not lateralized).

8. Temporal Development

• Onset: Congenital/early-childhood. Neutropenia and myelokathexis are present from infancy; clinical symptoms begin ~2 years of age; pattern is chronic and insidious (PMID: 30716504; PMID: 41451822).
• Progression: Neutropenia is stable and lifelong; infections are episodic/recurrent; bronchiectasis and HPV malignancy accumulate progressively with age. Warts typically emerge around age 11; malignancies in adulthood.
• Course pattern: Chronic, lifelong; complications progressive. No spontaneous remission except the exceptional chromothriptic reversion (PMID: 25662009).
• Critical periods / windows for intervention: Early pediatric diagnosis is associated with improved outcomes; newborn screening (low thymic emigrant T cells / TREC assay) can identify some infants, opening an early intervention window (PMID: 41451822).

9. Inheritance and Population

Epidemiology. WHIM is ultra-rare. Estimated prevalence is on the order of ~0.23 per million (Orphanet-class ultra-rare); only ~105 published cases had been reviewed at the time of the cohort analyses (PMID: 30716504). Precise incidence figures are unavailable owing to rarity and underdiagnosis.

Genetic etiology. - Inheritance: Autosomal dominant (PMID: 29066537). - Penetrance: Incomplete/variable — contributes to diagnostic delay (PMID: 41451822). - Expressivity: Highly variable, even within families (e.g., a Chinese kindred with four affected members showing heterogeneous phenotypes) (PMID: 39575248). - Genetic anticipation: Not a repeat-expansion disorder; anticipation not described. - Germline mosaicism / founder effects: Not established; p.R334X recurs as an independent mutational hotspot rather than a founder allele. - Carrier frequency: Not applicable (dominant); affected individuals are heterozygotes.

Population demographics. No strong ethnic predilection; reported worldwide, including the first documented case in a patient of African ancestry (PMID: 36793393) and familial Chinese cases (PMID: 39575248). Sex ratio approximately equal (autosomal). Age distribution spans infancy to adulthood, with diagnosis often in the second decade.

10. Diagnostics

Clinical/laboratory tests. - CBC with differential: Chronic severe neutropenia (ANC ~195 ± 102 cells/mm³ in cohort), lymphopenia, monocytopenia — panleukopenia (PMID: 30716504). - Immunoglobulins: Hypogammaglobulinemia (variable; may be normal). - Bone-marrow biopsy/aspirate — key diagnostic test: Myelokathexis — hypercellular marrow crowded with mature neutrophils showing hypersegmented, pyknotic (apoptotic) nuclei connected by thin chromatin strands. Detailed BM/peripheral-blood characterization of 30 CXCR4-variant patients confirms morphologic variability and correlates morphology with the CXCR4 internalization defect (PMID: 40239948). - Lymphocyte immunophenotyping: Decreased memory B cells, decreased naïve T cells, accumulation of effector-memory T cells, restricted TCR repertoire, and selective severe CD8 lymphopenia (PMID: 15026312; PMID: 37133343). - Imaging: Chest CT for bronchiectasis surveillance.

Genetic testing (confirmatory). Sequencing of CXCR4 — single-gene testing or inclusion in immunodeficiency/neutropenia gene panels; WES/WGS increasingly used. Detection of a heterozygous C-terminal truncating variant (e.g., p.R334X) confirms the diagnosis. Functional assays (impaired CXCL12-induced internalization; enhanced chemotaxis/calcium flux) support pathogenicity in ambiguous cases.

Clinical criteria / differential diagnosis. The diagnostic tetrad (WHIM), though hypogammaglobulinemia and/or warts may be absent. WHIM should be suspected in congenital neutropenia + lymphopenia even without hypogammaglobulinemia or warts (PMID: 29066537). Differentials include: - G6PC3 deficiency / severe congenital neutropenia — can show increased neutrophil CXCR4 expression and myelokathexis-like marrow but is autosomal recessive with multisystem features (PMID: 20616219). - GATA2 deficiency — monocytopenia, B/NK lymphopenia, generalized verrucosis, myeloid leukemia risk (PMID: 24359037). - CXCR2 loss-of-function — neutropenia + myelokathexis-like morphology (PMID: 41451234). - Other combined immunodeficiencies, epidermodysplasia verruciformis, WILD syndrome.

Screening. Newborn screening TREC assays (low thymic emigrant T cells) can flag some WHIM infants; cascade genetic testing of first-degree relatives once a proband variant is identified (PMID: 18535531; PMID: 41451822).

11. Outcome / Prognosis

Survival/mortality. With modern supportive care (G-CSF, IVIG) and now CXCR4 antagonists, WHIM is generally manageable and compatible with adult survival; there are no large formal survival curves. Principal threats to life are invasive HPV-driven malignancy and progressive lung disease.

Morbidity/function. Substantial: recurrent infections, IVIG dependence, refractory wart burden, and bronchiectasis in 27% with progressive lung-function decline (PMID: 30716504; PMID: 18535531).

Complications. Bronchiectasis; anogenital dysplasia and invasive cancer; HPV-related malignancies in 16% of patients; chronic humoral immunodeficiency (PMID: 30716504; PMID: 29066537).

Prognostic factors. Early pediatric diagnosis is associated with improved outcomes (PMID: 41451822). Degree of lymphopenia (particularly CD8) and cumulative HPV disease burden predict antiviral/malignancy risk. As a CID with lifetime risk for humoral deficiency, impaired antiviral defense, and malignancy, WHIM warrants long-term monitoring (PMID: 41451822).

12. Treatment

Pharmacotherapy — mechanism-based (CXCR4 antagonists)

Because pathology stems from CXCR4 hyperactivity, CXCR4 antagonism directly reverses leukocyte sequestration.

Mavorixafor (Xolremdi) — oral small-molecule selective CXCR4 antagonist; first FDA-approved targeted therapy for WHIM (26 April 2024), indicated for patients aged ≥12 years (PMID: 40223492; PMID: 40212179).

"On April 26th, 2024, Xolremdi (mavorixafor) capsules received its approval from US FDA, is the first targeted treatment specifically for patients aged ≥12 years with WHIM syndrome." (PMID: 40223492)

Clinical trial evidence:

"mavorixafor least squares (LS) mean TATANC was 15.0 hours and 2.8 hours for placebo (P < .001)" (PMID: 38643510)

Plerixafor (Mozobil, AMD3100) — injectable CXCR4 antagonist (FDA-approved for stem-cell mobilization); used off-label/investigationally in WHIM; provided the first pharmacologic proof that panleukopenia is CXCL12–CXCR4-signaling-dependent (PMID: 21890643; PMID: 24523241).

Conventional/supportive therapy. G-CSF (filgrastim) to raise neutrophil counts; IVIG for hypogammaglobulinemia/passive immunity; antibiotic prophylaxis; topical/ablative wart therapy (e.g., imiquimod); HPV vaccination; cancer surveillance. These have limited efficacy, require frequent administration, and carry patient burden — motivating targeted therapy (PMID: 40212179; PMID: 36793393).

Advanced / curative therapeutics

• Gene therapy — disease-allele inactivation. CRISPR/Cas9 inactivation of one Cxcr4 copy in HSPCs enriches WHIM-allele-inactivated cells in vivo while retaining long-term pluripotency — a proof-of-concept genetic cure exploiting CXCR4 haploinsufficiency's engraftment advantage (PMID: 36928087).

"To our knowledge, this is the first example of gene therapy for an autosomal dominant gain-of-function disease using a disease allele inactivation strategy in place of the less efficient disease allele repair approach" (PMID: 36928087)

• Natural cure precedent. Chromothriptic deletion of the disease allele in an HSC produced a spontaneous, durable cure of a WHIM patient (PMID: 25662009).

NCIT term suggestions: Mavorixafor (CXCR4-antagonist small molecule), Plerixafor (NCIT:C2411), Granulocyte colony-stimulating factor / Filgrastim (NCIT:C1512), Intravenous immunoglobulin therapy (NCIT:C603), Hematopoietic stem cell gene therapy.

13. Prevention

• Primary prevention: Not preventable (germline dominant). Genetic counseling for affected families; prenatal/preimplantation genetic testing possible when the familial variant is known.
• Secondary prevention (early detection): Newborn TREC screening flags some infants; cascade genetic testing of relatives; early bone-marrow evaluation in unexplained congenital neutropenia. Early diagnosis improves outcomes (PMID: 41451822).
• Tertiary prevention (complication avoidance): HPV vaccination, dermatologic/gynecologic surveillance for HPV dysplasia/malignancy, antibiotic prophylaxis, IVIG, pulmonary surveillance for bronchiectasis, and CXCR4-antagonist therapy to reduce infection burden (PMID: 29066537; PMID: 38643510).
• Counseling: Autosomal dominant recurrence risk (50% to offspring); genetic counseling recommended.

14. Other Species / Natural Disease

• Taxonomy / orthologs: Human CXCR4 (NCBI Gene 7852). Mouse ortholog Cxcr4 (NCBI Gene 12767) is well conserved; the CXCL12–CXCR4 axis and its role in leukocyte retention are evolutionarily conserved across vertebrates (mouse, zebrafish).
• Natural disease in other species: No naturally occurring WHIM-equivalent disease is documented in companion animals or wildlife (OMIA); WHIM in non-human species is experimentally induced, not natural.
• Comparative biology: The mechanism (CXCR4 gain-of-function → myelokathexis → neutropenia) is faithfully reproduced in engineered mice, supporting deep evolutionary conservation of the pathway. CXCR4 antagonism corrects analogous neutrophil abnormalities even in a CXCR2 loss-of-function mouse model, underscoring the conserved CXCR4/CXCR2 balance governing bone-marrow neutrophil release (PMID: 41451234).
• Transmission / zoonosis: Not applicable (genetic, non-transmissible).

15. Model Organisms

Mouse (Mus musculus, NCBI Taxon 10090). The principal WHIM model is a knock-in mouse carrying the human-equivalent Cxcr4 C-terminal truncation (R334X). - Phenotype recapitulation (strong): Reproduces peripheral neutropenia, lymphopenia, myelokathexis-like marrow morphology, selective severe CD8 lymphopenia, and heightened HPV (MmuPV1) susceptibility (PMID: 37133343; PMID: 39226327; PMID: 40239948). - Therapeutic validation: Oral CXCR4 antagonism corrects neutrophil and lymphocyte abnormalities and normalizes leukocyte trafficking in the WHIM mouse (PMID: 39588369); bone-marrow transplant from WT donors normalizes papillomavirus susceptibility, localizing the defect to hematopoietic cells (PMID: 39226327). - Competitive transplant models: Demonstrated that Cxcr4 haploinsufficiency confers a strong long-term HSC engraftment advantage — the biological basis for allele-inactivation gene therapy (PMID: 36928087).

Zebrafish (Danio rerio, NCBI Taxon 7955). Used to model CXCR4-axis immunomodulation; plerixafor reduced sepsis mortality in an LPS zebrafish model, supporting broader CXCR4-antagonist repurposing (PMID: 38963161).

In vitro / cellular models. Patient lymphoblastoid cell lines and heterologous CXCR4-expression systems established the gain-of-function signaling (calcium flux, ERK, chemotaxis), the GRK6/β-arrestin recruitment defect, and single-particle-tracking membrane-nanoclustering abnormality (PMID: 12692554; PMID: 19956569; PMID: 35588454).

Model limitations. Murine hypogammaglobulinemia and wart phenotypes are less faithful than the neutropenia/myelokathexis phenotype; HPV modeling requires the surrogate MmuPV1.

Resources: MGI (Cxcr4), IMPC, ZFIN (zebrafish cxcr4b).

Mechanistic Model (Synthesis)

   CXCR4 C-terminal truncating mutation (e.g., p.R334X, heterozygous, germline)
                              │  removes Ser/Thr phosphorylation cluster
                              ▼
   Failure to recruit GRK6 (GRK3 preserved) + delayed β-arrestin2  [PMID 19956569]
                              │
                              ▼
   Impaired receptor desensitization / internalization
                              │
                              ▼
   Sustained, exaggerated CXCL12→CXCR4 signaling
   (↑Ca²⁺, prolonged pERK, ↑chemotaxis; defective nanoclustering/gradient sensing)
                              │        [PMID 36883568, 12692554, 35588454]
                              ▼
   Failure of mature leukocyte egress from bone marrow  (CXCR4 = master retention signal)
                              │        [PMID 29734477, 21890643]
                              ▼
   MYELOKATHEXIS  →  peripheral NEUTROPENIA + PANLEUKOPENIA
             ┌────────────────────────────┴───────────────────────────┐
             ▼                                                          ▼
  Neutropenia + hypogammaglobulinemia                    Selective CD8>CD4 lymphopenia
   → recurrent bacterial infections                       (thymus/marrow sequestration)
   → pneumonia → BRONCHIECTASIS                            → failure to control HPV
                                                           → refractory WARTS → MALIGNANCY
             └───────────────► reversible by CXCR4 antagonism (mavorixafor) ◄──────────┘
                    curable by CXCR4-allele loss (chromothripsis / CRISPR)

Evidence Base

Limitations and Knowledge Gaps

1. Rarity limits epidemiology. Precise prevalence/incidence and formal survival statistics are lacking; estimates rest on <150 published cases.
2. Genetic heterogeneity. Rare WHIM-phenotype patients carry wild-type CXCR4 (PMID: 21178277); the responsible lesions (upstream regulators, other genes) are not fully mapped. No validated modifier genes explain the marked variable expressivity/incomplete penetrance.
3. Incomplete Ig/vaccine-response restoration. CXCR4 antagonists robustly correct cell counts but do not fully restore immunoglobulin levels or specific antibody responses (PMID: 24523241), leaving residual humoral risk.
4. Long-term antagonist data. Durability, malignancy-prevention efficacy, and pediatric (<12 y) data for mavorixafor remain to be established.
5. Model gaps. Mouse models under-represent the humoral/wart phenotype; HPV must be modeled via MmuPV1 surrogate.
6. Epigenetics/omics. No disease-specific methylation, transcriptomic, proteomic, or metabolomic signature has been formally defined for WHIM.

Proposed Follow-up Experiments / Actions

1. Long-term registry of mavorixafor-treated patients to quantify infection, bronchiectasis progression, HPV malignancy incidence, and survival versus historical G-CSF/IVIG cohorts.
2. Pediatric and non-CXCR4 (wild-type WHIM) trials to extend indication and identify alternative causal genes via WGS + functional CXCR4-pathway assays.
3. Advance CRISPR disease-allele-inactivation gene therapy (PMID: 36928087) toward first-in-human trials, leveraging the HSC engraftment advantage of CXCR4-haploinsufficient cells.
4. Mechanistic dissection of humoral defect — why antibody responses remain impaired despite corrected B-cell counts (germinal-center/stromal-niche studies).
5. Modifier-gene mapping across large kindreds to explain variable penetrance/expressivity.
6. Single-cell / spatial transcriptomics of WHIM bone marrow to characterize the stromal-niche disruption implicated in the combined immunodeficiency (PMID: 41451822).
7. HPV-directed prevention studies (early vaccination, surveillance protocols) given the 16% malignancy rate.

Report compiled from an autonomous five-iteration literature investigation (32 papers reviewed, 6 confirmed findings). Evidence types are labeled throughout: human clinical/cohort, model organism, in vitro, and regulatory.